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Abstract
Objective To examine whether supplementation with
multivitamins and multiminerals influences self reported days
of infection, use of health services, and quality of life in people
aged 65 or over.
Design Randomised, placebo controlled trial, with blinding of
participants, outcome assessors, and investigators.
Setting Communities associated with six general practices in
Grampian, Scotland.
Participants 910 men and women aged 65 or over who did not
take vitamins or minerals.
Interventions Daily multivitamin and multimineral
supplementation or placebo for one year.
Main outcome measures Primary outcomes were contacts with
primary care for infections, self reported days of infection, and
quality of life. Secondary outcomes included antibiotic
prescriptions, hospital admissions, adverse events, and
compliance.
Results Supplementation did not significantly affect contacts
with primary care and days of infection per person (incidence
rate ratio 0.96, 95% confidence interval 0.78 to 1.19 and 1.07,
0.90 to 1.27). Quality of life was not affected by
supplementation. No statistically significant findings were found
for secondary outcomes or subgroups.
Conclusion Routine multivitamin and multimineral
supplementation of older people living at home does not affect
self reported infection related morbidity.
Trial registration ISRCTN: 66376460.
Introduction
Respiratory tract and urinary tract infections are common
reasons for older people to visit their doctor,1 and viral
respiratory tract infections may precipitate hospital admission in
people with diabetes or cardiac or chronic obstructive
pulmonary diseases.2 Ageing is associated with dysregulation of
the immune system.3 Declining immunity can lead to infection
and depletion of nutritional reserves, which may already be sub-
optimal for host defences.4
The UK national diet and nutrition survey of older people
found evidence of multiple nutritional deficiencies.5 The
prevalence of deficiencies on blood testing ranged from about
10% for iron, vitamin C, red cell folate, thiamine, and vitamin D
in people living in the community to about 40% for vitamin C,
riboflavin, and vitamin D in those living in care. Deficiencies were
greater in Scotland than in southern England and greater in
those aged 75 or over.
At least 25% of older people in the United Kingdom take
nutritional supplements.5 Multivitamin andmultimineral supple-
ments are widely available and most brands have similar
contents.Whether such supplementation influences infections in
older people, particularly those not in nursing homes, is unclear
from randomised controlled trials. A recent systematic review
concluded that evidence for the routine use of multivitamin and
multimineral supplements in older people was weak and
conflicting and that further randomised controlled trials were
recommended.6 That review included trials by Chandra,7 8 whose
work has been questioned, leading one editor to retract a publi-
cation from one of the trials.7 9 An update to the review has been
published.10
Supplementation is a low cost option for improving
nutritional status. We undertook a pragmatic, randomised,
placebo controlled trial to examine whether supplementation
influences self reported infections, use of health services, and
quality of life in people aged 65 or over.
Participants and methods
Participants were recruited from six general practices in
Grampian, Scotland between February and December 2002. All
people aged 65 or over who were registered with the practices
were eligible, irrespective of chronic illness, unless their doctors
considered them too unwell. Exclusion criteria were use of vita-
min, mineral, or fish oil supplements in the previous three
months (one month in the case of water soluble vitamins) or
vitamin B12 injection in the past three months. Written informed
consent was collected.
Participants were recruited in their practice or at home by an
experienced nurse or dietician. Detailed instructions were given
about trial drugs, completion of daily diaries on infection and
any contacts with primary care for infections, which were
returned monthly, and the need to avoid vitamin or mineral sup-
plements from other sources during the trial.
Interventions
Participants were randomised to one tablet daily of a
multivitamin and multimineral supplement or a matched sorbi-
tol placebo. Supplements were 800 g vitamin A (acetate), 60 mg
vitamin C, 5 g vitamin D3, 10 mg vitamin E (D, L- tocopheryl
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acetate), 1.4 mg thiamin (mononitrate), 1.6 mg riboflavin, 18 mg
niacin (nicotinamide), 6 mg pantothenic acid (calcium
D-pantothenate), 2 mg pyridoxine (hydrochloride), 1 g vitamin
B12, 200 g folic acid, 14 mg iron (fumurate), 150 g iodine
(potassium iodide), 0.75 mg copper (gluconate), 15 mg zinc
(oxide), and 1 mg manganese (sulphate). The supplement
provided between 50-210% of UK reference nutrient intakes.11
Tablets were purchased from a commercial supplier and given to
participants for one year.
Outcomes
Predefined primary outcomes were number of contacts with pri-
mary care (doctor and other primary care workers, in person or
by phone) for infection, number of self reported days of
infection, and health related quality of life measured by the
EuroQol12 and SF-12.13 The EuroQol is a generic questionnaire
used to provide a single score for health related quality of life;
responses to the EuroQol were converted to a score using the
EuroQol UK population tariff.14 The SF-12 is a generic measure
of health related quality of life, including physical functioning,
social functioning, role limitations due to physical or emotional
problems, mental health, vitality, pain, and perception of general
health. We used prespecified procedures to code diaries for con-
tacts with primary care for infection and days of infection.
Predefined secondary outcomes were number of antibiotic
prescriptions in primary care, number of days that antibiotics
were prescribed, number of hospital admissions (including those
related to infection), number of days in hospital with infection,
number of infection related and all outpatient visits, adverse
events reported by participants, and compliance with trial drugs
(from diaries submitted monthly in all participants and tablet
count at six and 12 months in a random sample of 10% of par-
ticipants). Hospital data were obtained from computerised
patient administration systems and hospital and general practice
records.
General practice records were the only source of information
on contacts with primary care and antibiotic prescriptions in
over 94% of cases. Missing data were supplemented with partici-
pants’ diary information when deaths subsequently occurred
and the health board had removed the general practice notes, or
when participants gave details of antibiotic prescriptions missing
from the general practice records.
We carried out prespecified subgroup analyses for ages
65-74, 75-84, and ≥ 85 (the last two categories being
subsequently combined because few participants were aged
≥ 85), sex, type of accommodation (community, or in care, such
as a nursing home), and nutrition risk score (predictive of no
deficiency versus one deficiency in any of four groups).
We used a nutrition assessment questionnaire for detecting
older people at risk of nutritional deficiencies in vitamin C, vita-
min D, folate, or iron.15 We developed questions from responses
to a questionnaire and blood levels of nutritional status in a
healthy local population of older people without evidence of
infection.16
Sample size
We determined that we would need 900 participants to provide
80% power (5% significance, two-tailed) to detect a 25%
reduction in contacts with primary care for infection, where 40%
of this population in the United Kingdom seek help from
primary care for infections in any year.1 We assumed a dropout
rate of 20%. Our trial would be able to identify, with the same
power, relatively smaller effects on the other primary outcome of
days of infection.
Randomisation and blinding
At recruitment, participants were randomly allocated to
intervention or placebo by batch numbers generated by a
password protected computer program. The program could be
accessed by only the data programmer, blind to treatment
allocation. The identity of the tablets was concealed in a double
envelope sent by the manufacturer, which was kept locked in a
cabinet during the trial. Randomisation was stratified by general
practice and minimised by age (65-74, 75-84, ≥ 85), sex, and type
of accommodation (community or in care).
Assessors blind to trial allocation collected participant
reported primary care and hospital data. Statisticians undertook
analysis also blind to trial allocation. Blinding of researchers,
participants, and health professionals was maintained until com-
pletion of the analyses.
Quality assurance
The trial was conducted according to the Medical Research
Council’s guidelines for good clinical practice in clinical trials.17
All data collected were subjected to quality assurance
procedures. Two researchers independently entered a 10%
random sample of diaries and questionnaires using a secure
double data entry system. Agreement of 99% was achieved. We
Patients on general practitioner list (n=10 090)
After exclusions by general practitioner for being unwell (n=9597)
Not contacted because recruitment targets met (n=1030)
Letters sent (n=8567)
Replies (n=1523)
Ineligible (taking supplements) or declined (n=531)
Interviewed (n=992)
Randomised (n=910)
Vitamin and mineral
supplement (n=456)
Placebo
(n=454)
Stopped taking tablets but did
 not withdraw from trial (n=38)
Lost to follow-up (n=22)*:
Withdrew (n=14)
Died (n=8)
* Data were collected up to the point of full withdrawal
   Percentages relate to participants eligible to receive questionnaire
Stopped taking tablets but did
 not withdraw from trial (n=39)
Lost to follow-up (n=22)*:
Withdrew (n=18)
Died (n=4)
Analysis
Contacts with primary care for
 infection (n=453, 99%)
Patient returned diary on at
 least one occasion for self
 reported days of infection
 (n=451, 99%)
12 month questionnaires
 returned (n=415, 96%)
Analysis
Contacts with primary care for
 infection (n=452, 99%)
Patient returned diary on at
 least one occasion for self
 reported days of infection
 (n=450, 99%)
12 month questionnaires
 returned (n=409, 95%)
Randomisation
Ineligible (taking supplements) or declined (n=82)
Fig 1 Flow of participants through trial
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checked hospital records for all routinely collected data for eve-
ryone reporting a hospital admission or who had this
documented in their general practice records. We entered a ran-
dom sample of 10% of participants into the hospital’s patient
administration system to check whether any admissions had
been missed; none were found. We used prespecified
standardised procedures for extracting data from general
practice and hospital records.
Participants were asked at the end of the study whether they
knew their allocated treatment. Over 90% did not know or were
unable to guess.
Statistical analysis
Each comparison was by intention to treat, irrespective of
compliance with pill taking. Statistical significance for all primary
and secondary end points was based on two sided tests, with
2P ≤ 0.05. We applied stricter levels of significance (2P ≤ 0.01) to
subgroup analyses. For skewed continuous data, we calculated
median and interquartile ranges. To account for skewness, we
used negative binomial and poisson regression models to
estimate the incidence rate ratio and 95% confidence intervals
between groups, adjusting for the minimisation covariates, using
STATA.18 We accounted for an excess number of zeroes in an
outcome by using a zero inflated negative binomial or poisson
model when appropriate.19 A linear regression model in SPSS
was used to estimate the mean difference for health related qual-
ity of life measures between groups, after adjusting for baseline
values and the minimisation covariates.20
Results
Overall, 910 of 10 090 people (9%) aged 65 or over were
recruited (fig 1). Only 13% (n = 121) of participants were lost to
follow-up or reported stopping taking tablets. At least one diary
was provided by 99% (901) of participants, six diaries by 93%
(846), and 12 diaries by 89% (808).
Baseline data
The groups were well balanced at entry to the trial—for example,
median age 72 and 71 in intervention and placebo groups (table
1). In total, 4% of participants were aged 85 or older; 3% lived in
Table 1 Description of participants. Values are numbers (percentages) unless stated otherwise
Characteristics Supplement group Placebo group
n=456 n=454
Median (interquartile range) age (years) 72 (68.0-76.0) 71 (68.0-76.0)
Aged ≥85 19 (4) 16 (4)
Women 217 (48) 214 (47)
Mean (SD) body mass index (kg/m2) 28.2 (4.2) 27.9 (4.1)
n=456 n=453
Current smoker 57 (13) 63 (14)
Current No of different drugs taken: n=455 n=453
0-2 205 (45) 234 (52)
3-6 198 (44) 164 (36)
>6 52 (11) 55 (12)
Past and present chronic conditions: n=456 n=454
Hypertension 188 (41) 172 (38)
Heart disorders 137 (30) 130 (29)
Chest disorders 86 (19) 87 (19)
Diabetes 37 (8) 42 (9)
Cancer 46 (10) 46 (10)
Cerebrovascular disease 31 (7) 22 (5)
Chronic infection present at recruitment 42 (9) 38 (8)
Injection in past year to prevent influenza 432 (95) 423 (93)
Place of residence:
Community 440 (97) 439 (97)
Nursing home 16 (3) 15 (3)
Housing tenure:
Owner occupier 340 (75) 332 (73)
Public sector tenant* 88 (19) 92 (20)
Other 28 (6) 30 (7)
Nutrient at high risk of being deficient†:
Iron 73 (16) 37 (8)
Folate 25 (6) 21 (5)
Vitamin C 58 (13) 59 (13)
Vitamin D 70 (15) 49 (11)
At risk for any of above 145 (32) 117 (26)
*For example, council house tenant.
†On basis of micronutrient risk scores.
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Fig 2 Compliance on basis of diaries completed by participants
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nursing homes. Over half of the participants were men. More
than half took three or more different drugs daily. Over 93% had
had an injection in the previous year to prevent influenza.
On the basis of the questionnaire on nutrition, 32% of
participants in the intervention group (n = 145) and 26% in the
placebo group (n = 117) were at high risk of nutritional
deficiency for iron, folate, vitamin C, or vitamin D. Slightly more
people in the intervention group than in the placebo group were
at high risk of iron deficiency (16% versus 8%).
Compliance
We found no differences between the groups for compliance
with drug taking (figs 2 and 3). Compliance in participants still
taking tablets and returning information in diaries was over 91%
throughout the trial (fig 2). Compliance for all participants who
had not died was over 78% throughout the trial (fig 3). Compli-
ance as assessed by self report was consistent with tablet
counting.
Outcomes
We found no statistically significant effect from supplementation
on our primary outcomes of contacts with primary care staff
(mostly general practitioners and practice nurses) and days of
infection per person: incidence rate ratio 0.96, 95% confidence
interval 0.78 to 1.19 and 1.07, 0.90 to 1.27; table 2). Supplemen-
tation did not seem to affect quality of life (table 3).
None of the secondary outcomes significantly differed
between the groups (table 4).
Ancillary analyses and purported adverse events
Prespecified subgroup analyses for age, sex, and type of accom-
modation did not significantly differ between the groups (data
not shown). Neither did we find important differences for
subgroups on the basis of the nutrition risk score (no deficiency
versus one deficiency in any of the four groups; table 5).
Purported adverse events were not serious (headache,
insomnia, gout, for example). These events did not significantly
differ between the groups (table 4). Similar numbers of
participants in the groups died during the study (table 4).
Discussion
Regular use of commonly available multivitamin and multimin-
eral supplements by community dwelling older people who do
not already take supplements is unlikely to reduce the number of
self reported infections or associated use of health services. It
remains to be seen whether populations at higher risk of
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Fig 3 Compliance with zero intake imputed on non-return of diaries, including
withdrawals. Participants who died were included up to point of censoring
Table 2 Contacts with primary care for infections and days of infection (including type) in community dwelling people aged 65 or older receiving
multivitamin and multimineral supplementation or placebo for 12 months
Outcome measures
Supplement group Placebo group
Incidence rate ratio (95% CI)No
Median (interquartile range)
per person No
Median (interquartile range)
per person
Contacts with primary care for
infections*
879 1.0 (0-2) 930 1.0 (0-3) 0.96 (0.78 to 1.19); P=0.74
No in group n=453 — n=452 — —
No of days of self reported infection†: 8072 7.0 (0-24) 7871 8.0 (0-23) 1.07 (0.90 to 1.27); P=0.41
Upper respiratory tract infections 4068 1.0 (0-10) 3826 1.0 (0-10.25) —
Lower respiratory tract infections 1782 0 1436 0 —
Genitourinary tract infections 690 0 579 0 —
Skin infections 1106 0 1256 0 —
Other infections 426 0 774 0 —
No in group n=451 — n=450 — —
*Negative binomial model.
†Zero inflated negative binomial model.
Table 3 Quality of life measures for community dwelling people aged 65 or older receiving multivitamin and multimineral supplementation or placebo for 12
months
Quality of life measures
Supplement group Placebo group
Mean difference (95% CI) P valueNo Mean (SD) No Mean (SD)
Euroqol
Baseline 455 0.75 (0.2) 453 0.78 (0.2) — —
12 months 421 0.77 (0.2) 409 0.80 (0.2) −0.019 (−0.040 to 0.002) 0.08
SF-12
Baseline:
Physical 454 42.8 (11.4) 452 43.8 (10.7) — —
Mental 454 53.4 (8.7) 452 54.0 (8.7) — —
12 months:
Physical 415 43.7 (11.1) 412 44.3 (10.5) 0.07 (−0.90 to 1.03) 0.89
Mental 415 53.2 (9.1) 412 53.6 (9.2) −0.03 (−1.11 to 1.05) 0.96
Primary care
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infections, such as older people living in nursing homes, would
benefit from supplementation.
Our population had few people aged 85 or older or in nurs-
ing homes, who may be at higher risk of nutritional deficiency.5
Our population may have been healthier than people who did
not volunteer for the study. We did not, however, recruit people
already taking nutritional supplements (likely to be more than
25% of this age group5). By leaving out such people, we probably
excluded those with healthier diets.5 By using a simple question-
naire, we found that over 25% of the population was judged to be
at high risk of nutritional deficiency and potentially more likely
to benefit from supplementation, although this was not
supported by our subgroup analyses. The proportion of the trial
population at high risk of nutritional deficiency was similar to
that in a community survey of older people in the same region of
Scotland.16
Our participants were similar in age and place of residence to
those studied in a previous, disputed trial that reported beneficial
effects from supplementation.7 9 10 Participants in that trial had
levels of nutrient deficiencies (assessed by blood sampling) simi-
lar to people designated by our questionnaire as being at high
risk of nutrient deficiency. Unlike our trial, the supplement used
in the previous trial had four times the levels of vitamin E and
vitamin B12 and also contained selenium, magnesium, calcium,
and  carotene.7
Other randomised controlled trials have not found beneficial
effects of multivitamin and multimineral supplements on risk of
infection in community dwelling older people.21–23 A trial in
France reported no statistically significant effect of vitamin and
mineral supplements on infections.21 A study in the Netherlands
found that multivitamin and multimineral supplements had no
significant effect on acute respiratory tract infections.22 A US
study in primary care also found no significant effect from mul-
tivitamin and multimineral supplements on infections in people
aged 65 and over.23
Supplementation, especially of trace elements, has been
shown to reduce infections in older people in nursing care with
higher levels of nutritional deficiency.24 An effect of borderline
significance was reported by another trial.25 The effects of
supplementation with vitamin E also seem to differ between
community and nursing populations. In one study, vitamin E
seemed to worsen the severity of infections in people living in
the community,22 whereas it reduced the number of respiratory
tract infections in a trial of nursing home residents.26
We cannot exclude the possibility that the intakes provided in
the supplement were inadequate to affect the immune system.
Our trial was pragmatic, which examined participants’ self
reported infections and use of health services rather than
confirming infection by rigorous criteria seldom used in
Table 4 Data on prescriptions for antibiotics, hospital admissions, and infections in community dwelling people aged 65 or older receiving multivitamin and
multimineral supplementation or placebo for 12 months
Outcome measure
Supplement group Placebo group
Incidence rate ratio (95% CI) P valueNo
Median (interquartile)
range per person No
Median (interquartile range)
per person
No of prescriptions for antibiotics in
primary care*
619 (n=453) 1.0 (0.0-2.0) 641 (n=452) 0.0 (0.0-2.0) 0.98 (0.80 to 1.20) 0.85
Days of antibiotic prescribed per
person in primary care*
(n=197) 10.0 (7.0-20.5) (n=191) 10.0 (7.0-21.0) 0.93 (0.78 to 1.12) 0.45
No of hospital admissions 150 (n=453) 0 (0) 125 (n=452) 0 (0) 1.22 (0.89 to 1.67) 0.21
No of admissions for treatment of
infections†
22 (n=453) 0 (0) 23 (n=452) 0 (0) 0.97 (0.54 to 1.74) 0.92
Days of hospital stay for treatment
of infections*
(n=15) 9.0 (4.0-16.0) (n=16) 13.5 (6.25-34.5) 0.74 (0.40 to 1.37) 0.34
No of outpatient appointments for
treatment of infections‡
34 (n=453) 0 (0) 41 (n=452) 0 (0) 0.80 (0.38 to 1.67) 0.56
No of outpatient appointments§ 999 (n=440) 1.0 (0.0-3.0) 845 (n=435) 1.0 (0.0-3.0) 1.16 (0.92 to 1.47) 0.22
No of deaths¶ 8 (n=456) 4 (n=454) — 0.25
No of adverse events‡ 28 (n=456) 0 (0) 37 (n=454) 0 (0) 0.64 (0.22 to 1.93) 0.43
*Negative binomial model.
†Poisson model.
‡Zero inflated poisson model.
§Zero inflated negative binomial model.
¶Pearson’s 2=1.333.
Table 5 Subgroup analysis of contact with primary care for infection and days of infection by nutrition risk of community dwelling people aged 65 or older
receiving multivitamin and multimineral supplementation for 12 months
Subgroup
Supplement group Placebo group Incidence rate ratio at risk
versus not at risk (99% CI)† P valueLow risk High risk Low risk High risk
No of contacts with primary care
staff for infections*:
No at risk 309/453 144/453 336/452 116/452 — —
Median (interquartile range) per
person
1.0 (0.0-2.0) 1.0 (0.0-3.0) 1.0 (0.0-2.0) 1.0 (0.0-4.0) 1.16 (0.64 to 2.12) 0.52
No of infection days per person‡:
No at risk 307/451 144/451 334/450 116/450 — —
Median (interquartile range) per
person
7.0 (0.0-20.0) 7.5 (0.0-32.5) 7.0 (0.0-22.0) 13.0 (0.0-32.0) 1.04 (0.64 to 1.69) 0.84
High risk=at risk for one or more of following nutrient deficiencies: vitamin C, vitamin D, folate, or iron; low risk=not at risk for vitamin C, vitamin D, folate, or iron deficiency.
*Negative binomial model.
†Estimated from a treatment by nutrition risk interaction term.
‡Zero inflated negative binomial model.
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practice. Errors in self reporting should be balanced between the
two groups.
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What is already known on this topic
The vitamin and mineral status of older people may be
suboptimal, influencing immunity and risk of infection
It is unclear from previous trials in community dwelling
older people whether multivitamin and multimineral
supplements influence infection
What this study adds
Routine multivitamin and multimineral supplementation of
older people living at home is unlikely to affect self
reported infection related morbidity
Studies are needed in higher risk populations, such as older
people living in nursing homes
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